Pfizer
ロング

PFE set for a rebound

アップデート済
PFE beat analysts' estimates on EPS but provided an outlook that didn`t meet expectations. However, The Co expects revenues to grow by 7-9% in 2023. Considering its plans to boost business by acquiring SGEN, the current market cap looks attractive as a reverse to mean play and a fundamentally driven long-term investment case.
トレード終了: ストップロスに到達
Stop reached, if the price goes again above 41 I will be a buyer.
bullishideabuyideaFundamental AnalysisTechnical IndicatorslongterminvestingPFETrend Analysis

他のメディア:

免責事項